Mental health technology deals are increasingly sold on continuity. A larger platform can offer more providers, more forms of care, and fewer disruptions when a patient changes jobs, insurance, or treatment needs. That promise is compelling. It also creates a data governance problem that is easy to miss during integration.

When two platforms combine, the transaction may bring together therapy records, assessment responses, care navigation history, claims, wearable streams, voice data, behavioral signals, and algorithmic risk scores. Each dataset was collected in a particular relationship and for a particular purpose. Corporate ownership may change in a day. The meaning of the patient’s permission does not.

Recent deals show how quickly the issue is becoming practical. Spring Health’s acquisition of Alma creates a platform supporting more than 170 million people and plans to use shared infrastructure, data, and technology to improve continuity. Such combinations may improve care while also expanding the ways that highly sensitive information can be connected, interpreted, and reused.

Mental health technology M&A therefore needs a consent continuity standard. Consent continuity means preserving the original context, purpose, limits, and patient choices attached to data as it moves into a new corporate and technical environment. It is not another generic notice sent after closing. It is an integration control that should be completed before datasets, analytics pipelines, or AI models are combined.

Most integration teams begin with a technical inventory: what data exists, where it sits, and whether the fields can be mapped. A consent continuity review adds the questions that determine whether those fields should be joined at all.

Source link